1. Home
  2. ZLAB vs VLYPO Comparison

ZLAB vs VLYPO Comparison

Compare ZLAB & VLYPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ZLAB
  • VLYPO
  • Stock Information
  • Founded
  • ZLAB 2013
  • VLYPO N/A
  • Country
  • ZLAB China
  • VLYPO United States
  • Employees
  • ZLAB N/A
  • VLYPO 3732
  • Industry
  • ZLAB Biotechnology: Pharmaceutical Preparations
  • VLYPO Major Banks
  • Sector
  • ZLAB Health Care
  • VLYPO Finance
  • Exchange
  • ZLAB Nasdaq
  • VLYPO Nasdaq
  • Market Cap
  • ZLAB 3.5B
  • VLYPO N/A
  • IPO Year
  • ZLAB 2017
  • VLYPO N/A
  • Fundamental
  • Price
  • ZLAB $29.24
  • VLYPO $25.11
  • Analyst Decision
  • ZLAB Buy
  • VLYPO
  • Analyst Count
  • ZLAB 4
  • VLYPO 0
  • Target Price
  • ZLAB $47.37
  • VLYPO N/A
  • AVG Volume (30 Days)
  • ZLAB 1.2M
  • VLYPO N/A
  • Earning Date
  • ZLAB 05-08-2025
  • VLYPO N/A
  • Dividend Yield
  • ZLAB N/A
  • VLYPO N/A
  • EPS Growth
  • ZLAB N/A
  • VLYPO N/A
  • EPS
  • ZLAB N/A
  • VLYPO N/A
  • Revenue
  • ZLAB $418,326,000.00
  • VLYPO N/A
  • Revenue This Year
  • ZLAB $44.43
  • VLYPO N/A
  • Revenue Next Year
  • ZLAB $48.68
  • VLYPO N/A
  • P/E Ratio
  • ZLAB N/A
  • VLYPO N/A
  • Revenue Growth
  • ZLAB 43.72
  • VLYPO N/A
  • 52 Week Low
  • ZLAB $15.65
  • VLYPO N/A
  • 52 Week High
  • ZLAB $39.77
  • VLYPO N/A
  • Technical
  • Relative Strength Index (RSI)
  • ZLAB 42.71
  • VLYPO 62.15
  • Support Level
  • ZLAB $27.61
  • VLYPO $24.55
  • Resistance Level
  • ZLAB $32.02
  • VLYPO $25.39
  • Average True Range (ATR)
  • ZLAB 1.23
  • VLYPO 0.29
  • MACD
  • ZLAB -0.18
  • VLYPO 0.12
  • Stochastic Oscillator
  • ZLAB 23.41
  • VLYPO 82.83

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.

About VLYPO Valley National Bancorp 5.50% Fixed-to-Floating Rate Non-Cumulative Perpetual Preferred Stock Series B

Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.

Share on Social Networks: